Neurocrine Biosciences | Capitaux Propres Et Réserves



Equity Capital And Reserves Changement Date
AbbVie USD 3.32B 2.71B 2024-12
Acadia Pharmaceuticals USD 732.79M 155.61M 2024-12
Agios Pharmaceuticals USD 1.54B 85.72M 2024-12
ALKERMES USD 1.46B 172.88M 2024-12
Alnylam Pharmaceuticals USD 67.09M 34.73M 2024-12
Amgen USD 5.88B 1.65B 2024-12
Biogen USD 16.72B 357.1M 2024-12
BioMarin Pharmaceutical USD 5.66B 244.59M 2024-12
Cytokinetics USD -135372000 121.46M 2024-12
Dynavax Technologies USD 596.8M 84.63M 2024-12
Exelixis USD 2.24B 31.22M 2025-01
Gilead Sciences USD 19.33B 856M 2024-12
Halozyme Therapeutics USD 363.82M 88.88M 2024-12
Incyte USD 3.45B 276.41M 2024-12
Intra Cellular Therapies USD 1.15B 3.63M 2024-12
Ionis Pharmaceuticals USD 588.35M 74.12M 2024-12
Neurocrine Biosciences USD 2.59B 129.2M 2024-12
Pfizer USD 88.2B 4.08B 2024-12
Prothena USD 486.93M 47.44M 2024-12
Regeneron Pharmaceuticals USD 29.35B 27.7M 2024-12
Repligen USD 2.02B 30.33M 2024-09
Sarepta Therapeutics USD 1.53B 306.67M 2024-12
Teva Pharmaceutical Industries USD 5.72B 344M 2024-12
Ultragenyx Pharmaceutical USD 255.3M 91.53M 2024-12
Vertex Pharmaceuticals USD 16.41B 778.7M 2024-12



Neurocrine Biosciences Capitaux Propres Et Réserves - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Mar 2025.